Evidence map›Paper›PMID 27917408›Full record

ArticleACS omega2016

Prostate-Specific Membrane Antigen Targeted Polymersomes for Delivering Mocetinostat and Docetaxel to Prostate Cancer Cell Spheroids.

Fataneh Karandish, Manas K Haldar, Seungyong You, Amanda E Brooks, Benjamin D Brooks, Bin Guo, Yongki Choi, Sanku Mallik

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Fataneh KarandishDepartment of Pharmaceutical Sciences and Department of Physics, North Dakota State University , 1401 Albrecht Blvd., Fargo, North Dakota 58102, United States.
Manas K HaldarDepartment of Pharmaceutical Sciences and Department of Physics, North Dakota State University , 1401 Albrecht Blvd., Fargo, North Dakota 58102, United States.
Seungyong YouDepartment of Pharmaceutical Sciences and Department of Physics, North Dakota State University , 1401 Albrecht Blvd., Fargo, North Dakota 58102, United States.
Amanda E BrooksDepartment of Pharmaceutical Sciences and Department of Physics, North Dakota State University , 1401 Albrecht Blvd., Fargo, North Dakota 58102, United States.
Benjamin D BrooksDepartment of Pharmaceutical Sciences and Department of Physics, North Dakota State University , 1401 Albrecht Blvd., Fargo, North Dakota 58102, United States.
Bin GuoDepartment of Pharmaceutical Sciences and Department of Physics, North Dakota State University , 1401 Albrecht Blvd., Fargo, North Dakota 58102, United States.
Yongki ChoiDepartment of Pharmaceutical Sciences and Department of Physics, North Dakota State University , 1401 Albrecht Blvd., Fargo, North Dakota 58102, United States.
Sanku MallikDepartment of Pharmaceutical Sciences and Department of Physics, North Dakota State University , 1401 Albrecht Blvd., Fargo, North Dakota 58102, United States.
North Dakota State University · US

Funding

Echogenic Polymersomes for Triggered Contents ReleaseR01GM114080 · NIGMS · NORTH DAKOTA STATE UNIVERSITY · PI MALLIK, SANKU, SARKAR, KAUSIK · 2015 to 2023
$2.6M
NIGMS NIH HHS R01 GM114080
6 · The paper itself

Abstract

Prostate cancer cells overexpress the prostate-specific membrane antigen (PSMA) receptors on the surface. Targeting the PSMA receptor creates a unique opportunity for drug delivery. Docetaxel is a Food and Drug Administration-approved drug for treating metastatic and androgen-independent prostate cancer, and mocetinostat is a potent inhibitor of class I histone deacetylases. In this study, we prepared reduction-sensitive polymersomes presenting folic acid on the surface and encapsulating either docetaxel or mocetinostat. The presence of folic acid allowed efficient targeting of the PSMA receptor and subsequent internalization of the polymeric vesicles in cultured LNCaP prostate cancer cell spheroids. The intracellular reducing agents efficiently released docetaxel and mocetinostat from the polymersomes. The combination of the two drug-encapsulated polymersome formulations significantly (

Identifiers

PMID27917408
PMCPMC5131327
OpenAlexW2554936458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.